All In Biotech

Drug Trial Radar · NCT05276219

DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure

Vasodilatation or Loop-Diuretics for Initial Treatment of Pulmonary Congestion Due to Acute Heart Failure - A Randomized Placebo-Controlled Trial

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,041 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,041

Planned (sponsor's estimate)

Start

Sep 14, 2023

Primary completion

May 1, 2027

Study completion May 1, 2027

Sponsor

Lead sponsor
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Zealand University Hospital; Copenhagen University Hospital, Hvidovre; Herlev Hospital; Bispebjerg Hospital
First posted
Mar 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DECONGEST-AHF compares three initial treatments for adults admitted with suspected pulmonary congestion due to acute heart failure: intravenous furosemide, intravenous isosorbide dinitrate, or both medicines together. The aim is to determine which treatment gives patients the most days alive and outside hospital during the first 30 days. The trial is investigator-initiated, multicentre, randomised and blinded, with 1,041 participants allocated equally to three groups. During the first six hours, participants receive repeated boluses of 40 mg furosemide with nitrate placebo, 3 mg isosorbide dinitrate with furosemide placebo, or both active medicines. Doses are repeated at the treating physician's discretion within the protocol limits. Other usual care continues, and treatment may be stopped early if clinically required. An embedded substudy will examine early clinical and haemodynamic responses in 79 participants from the main trial, using repeated bedside measurements during the first 360 minutes. The main trial treatment groups and primary outcome are unchanged.

Conditions

  • Pulmonary Edema
  • Congestive Heart Failure
  • Acute Heart Failure

Interventions

  • Furosemide InjectionDrug

    A diuretic (iv furosemide) strategy for decongestion in acute heart failure

  • Isosorbide DinitrateDrug

    Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure

  • Furosemide and isosorbide dinitrateDrug

    Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Days alive and outside hospitalTime frame: 30 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Herlev University Hospital

    Herlev, Denmark · Recruiting

  • Nordsjællands Hospital

    Hillerød, Denmark · Active not recruiting

  • Hvidovre Hospital

    Hvidovre, Denmark · Recruiting

  • Roskilde Hospital

    Roskilde, Denmark · Recruiting

  • Bispebjerg Hospital

    Copenhagen, Copenhagen, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.